Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

trastuzumab

- PMLiVE

Novartis raises pressure in Pfizer’s Ibrance with new Kisqali data

Women on Kisqali were found to have a longer PFS than those on hormonal therapy alone

Roche Basel Switzerland

Roche gets FDA OKs for Alecensa and Zelboraf

Gains US licences for first-line use in lung cancer and a rare blood cancer

- PMLiVE

Novartis files CAR-T therapy CTL109 in Europe

Analysts predict Kymriah could become a $1bn-plus product in Europe

Roche Basel Switzerland

Smartphone monitoring shows its worth in Roche MS trial

The tool uses smartphone sensors to measure neurological tests

EU flag

EU’s 10-year paediatric meds report – not bad, but can do better

Paper highlights the lack of ‘major therapeutic advances’ in children’s medicine

Roche Basel Switzerland

Roche biggest pharma R&D spender in PwC survey

Pharma giant on track to spend 21.9% of its total revenue on research this year

AstraZeneca AZ

AZ and MSD win FDA priority review for Lynparza in breast cancer

Could become the first PARP inhibitor to be approved in the US for the disease

- PMLiVE

CHMP recommends Teva’s generic version of Astellas’ Advagraf

Committee backs the drug for transplant rejection prophylaxis

Roche Basel Switzerland

Roche wins CHMP nod for Alecensa licence extensions

Lung cancer monotherapy set for a broader European label

Roche and J&J picked for ‘revolutionary’ digital health pilot

Firms will line up alongside Apple, Fitbit, Samsung and Verily in FDA pre-certification programme

Roche - Basel

Roche and J&J picked for ‘revolutionary’ digital health pilot

Firms will line up alongside Apple, Fitbit, Samsung and Verily in FDA pre-certification programme

- PMLiVE

AAA’s orphan drug Lutathera wins EU green light

The first-in-class drug treats adults with GEP-NET

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links